=========================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------
AMENDMENT NO. 8 TO
SCHEDULE 14D-1
TENDER OFFER STATEMENT
PURSUANT TO SECTION 14(D)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
and
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
----------------------
Chiron Corporation
(Name of Subject Company)
----------------------
CIBA Biotech Partnership, Inc.
CIBA-GEIGY Corporation
CIBA-GEIGY Limited
(Bidders)
----------------------
Common Stock, Par Value $0.01 Per Share
(including the associated preferred stock purchase rights)
(Title of Class of Securities)
----------------------
170040109
(CUSIP Number of Class of Securities)
----------------------
Dr. Herbert Gut
CIBA-GEIGY Limited
Klybeckstrasse 141
CH-4002, Basel
Switzerland
41-61-696-1111
(Name, Address and Telephone Number of Persons Authorized to
Receive Notices and Communications on Behalf of Bidders)
----------------------
Copies to:
Philip A. Gelston, Esq.
Cravath, Swaine & Moore
Worldwide Plaza
825 Eighth Avenue
New York, New York 10019
(212) 474-1000
----------------------
=========================================================================
Page 1 of ___ pages
Exhibit Index on Page ___
<PAGE>
Ciba-Geigy Limited ("Ciba"), Ciba-Geigy Corporation
("CGC") and CIBA Biotech Partnership, Inc. (the "Purchaser")
hereby amend and supplement their combined Tender Offer Statement
on Schedule 14D-1 and Statement on Schedule 13D originally filed
on November 28, 1994 and as previously amended, with respect to
the offer by the Purchaser to purchase 11,860,467 shares of
Common Stock, par value $0.01 per share, of Chiron Corporation, a
Delaware corporation (the "Company"), together with the
associated preferred stock purchase rights issued pursuant to the
Rights Agreement dated as of August 25, 1994, as amended, between
the Company and Continental Stock Transfer & Trust Company, as
Rights Agent, upon the terms and subject to the conditions set
forth in the Offer to Purchase dated November 28, 1994. All
capitalized terms not otherwise defined herein have the meanings
assigned to them in the Offer to Purchase.
Item 7. Contracts, Arrangements, Understandings or Relationships
with Respect to the Subject Company's Securities
Item 7 of the combined Schedule 14D-1 and Schedule 13D
is hereby amended and supplemented by adding the following at the
end thereof:
On July 12, 1996, a letter (the "Letter") was delivered
on behalf of Ciba and Sandoz Limited ("Sandoz") to the European
Commission (the "EC") in connection with the pending review by
the EC of the proposed merger of Ciba and Sandoz to form Novartis
AG ("Novartis"). The Letter describes an arrangement between Ciba
and Sandoz to cause Novartis to use its legal and contractual
possibilities of influence with respect to the Company so that an
affiliate of the Company may grant non-exclusive licenses to
interested entities under each of the European patents (if any)
that may be issued and the national patents (if any) that may be
derived therefrom that are based in each case on the
international patent applications No. WO 89/09271 and WO 90/07936
re. HSTK-(Herpes simplex Thymidine Kinase) Gentherapy for tumors.
This obligation is to last for a period of ten years from the
grant date of such patents. The text of the Letter and a
corresponding English translation are attached as Exhibit (c)(11)
hereto and incorporated herein by reference.
Page 2 of ___ pages
<PAGE>
Item 11. Material to be Filed as Exhibits.
(c)(11) Text of Letter dated July 10, 1996 delivered to
the European Commission on behalf of Ciba and Sandoz on July 12,
1996, and corresponding English language translation.
Page 3 of ___ pages
<PAGE>
SIGNATURES
After due inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this
statement is true, complete and correct.
Dated: July 18, 1996
CIBA Biotech Partnership, Inc.
by /s/John J. McGraw
--------------------------
Name: John J. McGraw
Title: Vice President
CIBA-GEIGY LIMITED
by /s/Peter Rupprecht
--------------------------
Name: Peter Rupprecht
Title: Corporate Counsel
by /s/Dr. Peter Rudolf
--------------------------
Name: Dr. Peter Rudolf
Title: Senior Division Counsel
CIBA-GEIGY Corporation
by /s/John J. McGraw
-------------------------
Name: John J. McGraw
Title Vice President and
General Counsel
Page 4 of ___ pages
<PAGE>
EXHIBIT INDEX
Exhibit Sequentially
Number Exhibit Name Numbered Page
(c)(11) Text of Letter dated July
10, 1996 delivered to the
European Commission on July 12,
1996 on behalf of Ciba and
Sandoz, and corresponding English
language translation.............
Page 5 of ___ pages
<PAGE>
Exhibit (c)(11)
10. Juli 1996
Fall IV/M.737 Sandoz/Ciba-Geigy
Sehr geehrte Damen und Herren,
wir schreiben Ihnen im Auftrag von Ciba und Sandoz.
Beide Unternehmen erklaren hiermit verbindlich fur die
Novartis AG folgendes: Novartis wird ihre rechtlichen und
vertraglichen Einflussmoglichkeiten, die sie aufgrund ihrer
Beteiligung an Chiron Corporation, Emeryville, California/USA,
und uber die von ihr benannten Board- Mitglieder hat, so ausuben,
dass die Chiron-Tochtergesellschaft Viagene interessierten
Unternehmen nicht-ausschliessliche Lizenzen zu handelsublichen
Bedingungen fur jedes europaische Patent und daraus abgeleitete
nationale Patente erteilt, die auf den internationalen
Patentanmeldungen Nrn. WO 89/09271 und WO 90/07936 fur HSTK-
(Herpes simplex Thymidine Kinase) Gentherapie fur Tumore beruhen.
Diese Verpflichtung steht unter dem Vorbehalt, da(beta)
das Verhalten von Novartis und der von ihr benannten
Board-Mitglieder nach amerikanischem Recht im besten Interesse
von Chiron und ihrer Aktionare liegen muss. Sie soll fur 10 Jahre
ab Erteilung der europaischen Patente gelten.
Mit freundlichen Grussen
Dr. Bechtold
<PAGE>
TRANSLATION
To the Commission of the European
Committees (GD IV) -Competition-
Directorate B-Task Force Merger
Control 150 Avenue de Cortenberg
B-1040 Brussels
July 10, 1996
Case IV/M.737 Sandoz/Ciba-Geigy
Ladies and Gentlemen:
We write to you on behalf of Ciba and Sandoz.
Both enterprises declare the following which shall be
committing on Novartis AG: Novartis will use its legal and
contractual possibilities of influence which it has based on its
participation in Chiron Corporation, Emeryville, California, USA,
and via the board members nominated by it, so that Viagene, a
daughter company of Chiron will grant non-exclusive licenses to
interested companies under each of its European patents and the
national patents derived therefrom which are based on the
international patent applications No. WO 89/09271 and WO 90/07936
re. HSTK-(Herpes simplex Thymidine Kinase) Gentherapy for tumors.
This obligation is subject to the proviso that the
conduct of Novartis and the board members appointed by Novartis
must, according to the US law, be in the best interest of Chiron
and its shareholders. The obligation shall last for 10 years from
the grant of the said European Patents.
With kind regards,
Dr. Bechtold
